MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
LeMaitre Vascular Balance Sheet 2011-2026 | LMAT
Annual Balance Sheet LeMaitre Vascular
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
145 M | -5.17 M | -2.54 M | 2.08 M | 10.7 M | 3.93 M | -26.3 M | -19.1 M | -24.3 M | -27.5 M | -18.7 M | -14.7 M | -16.4 M | -20.1 M |
Long Term Debt |
168 M | 16.6 M | 14.7 M | 14.1 M | 35.5 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.68 M | 2.47 M | 1.89 M | 1.87 M | 1.95 M | 1.76 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 19.3 M | 3.1 M | 3.36 M | 3.94 M | 2.45 M | 3.24 M | 3.71 M | 1.78 M | 1.06 M |
Total Current Liabilities |
30.6 M | 29.9 M | 25.3 M | 21.8 M | 25.1 M | 20.9 M | 19.8 M | 13.2 M | 10.5 M | 10.4 M | 10 M | 10.2 M | 8.39 M | 6.54 M |
Total Liabilities |
215 M | 48.9 M | 42.3 M | 38.7 M | 80.2 M | 40.2 M | 22.9 M | 16.6 M | 14.4 M | 12.8 M | 13.3 M | 13.9 M | 10.2 M | 7.6 M |
Deferred Revenue |
- | - | - | - | - | - | 552 K | - | - | - | - | - | - | - |
Retained Earnings |
145 M | 115 M | 97.8 M | 88.1 M | 70.6 M | 57 M | 45.8 M | 28.3 M | 15.3 M | 8.16 M | 3.25 M | -667 K | -3.87 M | -6.44 M |
Total Assets |
552 M | 347 M | 310 M | 293 M | 253 M | 188 M | 153 M | 126 M | 102 M | 90.7 M | 81.5 M | 70.5 M | 63.1 M | 59.7 M |
Cash and Cash Equivalents |
25.6 M | 24.3 M | 19.1 M | 13.9 M | 26.8 M | 11.8 M | 26.3 M | 19.1 M | 24.3 M | 27.5 M | 18.7 M | 14.7 M | 16.4 M | 20.1 M |
Book Value |
337 M | 298 M | 268 M | 254 M | 173 M | 148 M | 130 M | 110 M | 87.5 M | 77.9 M | 68.2 M | 56.6 M | 52.9 M | 52.1 M |
Total Shareholders Equity |
337 M | 298 M | 268 M | 254 M | 173 M | 148 M | 130 M | 110 M | 87.5 M | 77.9 M | 68.2 M | 56.6 M | 52.9 M | 52.1 M |
All numbers in USD currency
Quarterly Balance Sheet LeMaitre Vascular
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
168 M | 168 M | 168 M | 15.6 M | 15.8 M | - | 14.1 M | 14.4 M | 14.4 M | 14.7 M | 14.9 M | - | 13.7 M | 14.1 M | 14.6 M | 15.1 M | 14.4 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 14 M | 14 M | 14 M | 14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
219 M | 215 M | 208 M | 46 M | 43.5 M | - | 45.4 M | 42.6 M | 40.7 M | 42.3 M | 40.8 M | - | 34.7 M | 38.7 M | 40.4 M | 60.7 M | 69.8 M | 80.2 M | 80.2 M | 80.2 M | 80.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 188 K | 368 K | 552 K | 752 K | 951 K | 552 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
174 M | 161 M | 152 M | 138 M | 130 M | - | 110 M | 106 M | 101 M | 97.8 M | 94.9 M | - | 91.4 M | 88.1 M | 84.4 M | 80.3 M | 74.2 M | 70.6 M | 70.6 M | 70.6 M | 70.6 M | 57 M | 57 M | 57 M | 57 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 8.16 M | 8.16 M | 8.16 M | 8.16 M | 3.25 M | 3.25 M | 3.25 M | 3.25 M | -667 K | -667 K | -667 K | -667 K | -3.87 M | -3.87 M | -3.87 M | -3.87 M | -6.44 M | -6.44 M | -6.44 M | -6.44 M |
Total Assets |
598 M | 578 M | 556 M | 377 M | 363 M | - | 334 M | 326 M | 315 M | 310 M | 302 M | - | 292 M | 293 M | 289 M | 247 M | 247 M | 253 M | 253 M | 253 M | 253 M | 188 M | 188 M | 188 M | 188 M | 153 M | 153 M | 153 M | 153 M | 126 M | 126 M | 126 M | 126 M | 102 M | 102 M | 102 M | 102 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 70.5 M | 70.5 M | 70.5 M | 70.5 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 59.7 M | 59.7 M | 59.7 M | 59.7 M |
Cash and Cash Equivalents |
25.5 M | 27.2 M | 25.3 M | 21 M | 22.3 M | - | 18.1 M | 19.5 M | 16.7 M | 19.1 M | 16.9 M | - | 15.6 M | 13.9 M | 17.4 M | 21.5 M | 23.5 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 24.3 M | 24.3 M | 24.3 M | 24.3 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M |
Book Value |
379 M | 363 M | 348 M | 331 M | 320 M | - | 289 M | 284 M | 274 M | 268 M | 261 M | - | 258 M | 254 M | 249 M | 186 M | 178 M | 173 M | 173 M | 173 M | 173 M | 148 M | 148 M | 148 M | 148 M | 130 M | 130 M | 130 M | 130 M | 110 M | 110 M | 110 M | 110 M | 87.5 M | 87.5 M | 87.5 M | 87.5 M | 77.9 M | 77.9 M | 77.9 M | 77.9 M | 68.2 M | 68.2 M | 68.2 M | 68.2 M | 56.6 M | 56.6 M | 56.6 M | 56.6 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M |
Total Shareholders Equity |
379 M | 363 M | 348 M | 331 M | 320 M | 309 M | 289 M | 284 M | 274 M | 268 M | 261 M | 258 M | 258 M | 254 M | 249 M | 186 M | 178 M | 173 M | 173 M | 173 M | 173 M | 148 M | 148 M | 148 M | 148 M | 130 M | 130 M | 130 M | 130 M | 110 M | 110 M | 110 M | 110 M | 87.5 M | 87.5 M | 87.5 M | 87.5 M | 77.9 M | 77.9 M | 77.9 M | 77.9 M | 68.2 M | 68.2 M | 68.2 M | 68.2 M | 56.6 M | 56.6 M | 56.6 M | 56.6 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of LeMaitre Vascular, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
$ 19.84 | -1.24 % | $ 10.1 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
$ 151.29 | 0.93 % | $ 3.69 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 9.47 | 8.85 % | $ 191 M | USA |
 |
Alcon
ALC
|
$ 79.26 | -2.12 % | $ 40.4 B |  Schweiz |
 |
InfuSystem Holdings
INFU
|
$ 8.16 | -1.21 % | $ 168 M | USA |
 |
AtriCure
ATRC
|
$ 37.18 | 0.68 % | $ 1.75 B | USA |
 |
electroCore
ECOR
|
$ 6.87 | 3.15 % | $ 37.9 K | USA |
 |
Haemonetics Corporation
HAE
|
$ 65.53 | -1.7 % | $ 3.3 B | USA |
 |
AngioDynamics
ANGO
|
$ 10.47 | 1.01 % | $ 428 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 81.43 | 0.42 % | $ 4.74 B | USA |
 |
The Cooper Companies
COO
|
$ 80.43 | -1.17 % | $ 16 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.51 | 0.98 % | $ 21.6 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 118.49 | -0.79 % | $ 5.74 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.95 | 5.56 % | $ 220 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.74 | 6.49 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 157.37 | 1.85 % | $ 4.91 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 13.62 | -1.52 % | $ 654 M | USA |
 |
Masimo Corporation
MASI
|
$ 137.44 | 0.08 % | $ 7.33 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 497.56 | -1.32 % | $ 177 B | USA |
 |
STERIS plc
STE
|
$ 263.8 | 0.4 % | $ 26 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.83 | 1.39 % | $ 18.7 M |  Israel |
 |
Nephros
NEPH
|
$ 4.63 | 7.42 % | $ 48.1 M | USA |
 |
Utah Medical Products
UTMD
|
$ 61.6 | 0.88 % | $ 224 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.27 | -4.98 % | $ 21.5 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.19 | -1.15 % | $ 3.99 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.28 | -1.56 % | $ 2.5 B | USA |
 |
Pro-Dex
PDEX
|
$ 40.12 | 2.27 % | $ 132 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 201.89 | -0.82 % | $ 58.1 B | USA |
 |
Repligen Corporation
RGEN
|
$ 151.0 | 1.09 % | $ 8.41 M | USA |
 |
ResMed
RMD
|
$ 251.72 | -2.55 % | $ 36.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 22.42 | 2.84 % | $ 1.03 B | USA |
 |
Stereotaxis
STXS
|
$ 2.23 | 1.59 % | $ 180 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | -0.31 % | $ 21 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.13 | -4.33 % | $ 891 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 103.43 | -0.92 % | $ 4.84 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 233.58 | 1.04 % | $ 17.1 B | USA |